|
gptkbp:instanceOf
|
gptkb:chemical_compound
antitubercular drug
|
|
gptkbp:approvalYear
|
1952
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J04AK01
|
|
gptkbp:CASNumber
|
98-96-4
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
antitubercular agents
|
|
gptkbp:chemicalFormula
|
gptkb:C5H5N3O
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
severe hepatic impairment
acute gout
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:drugClass
|
antimycobacterial
|
|
gptkbp:drugInteraction
|
may increase hepatotoxicity with rifampicin
|
|
gptkbp:eliminationHalfLife
|
9-10 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstLineTreatmentFor
|
gptkb:Mycobacterium_tuberculosis
|
|
gptkbp:hasInChIKey
|
LGTWKNHPLVQVRX-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
C1=CN=C(C=N1)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pyrazinamide
|
|
gptkbp:IUPACName
|
gptkb:pyrazine-2-carboxamide
|
|
gptkbp:KEGGID
|
D00410
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
disrupts Mycobacterium tuberculosis membrane transport and energy production
|
|
gptkbp:meltingPoint
|
190-195°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
123.11 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:Mycobacterium_bovis
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1540
1046
1018
DB00339
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
hepatotoxicity
arthralgia
hyperuricemia
|
|
gptkbp:solubility
|
14.5 mg/mL at 25°C
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:UNII
|
T6Z7Z6XBU6
|
|
gptkbp:usedFor
|
treatment of tuberculosis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:rifampicin
|
|
gptkbp:bfsLayer
|
5
|